Woo Ile Park

Title: **Inventor Woo Ile Park: Pioneering Innovations in Thrombotic Disease Treatment**

Introduction

Woo Ile Park, an innovative inventor based in Gyeonggi-do, South Korea, has made significant contributions to the field of pharmacology. He holds one patent that focuses on a novel compound designed to inhibit platelet aggregation, an important factor in the treatment of thrombotic diseases. His work is vital for improving therapies aimed at preventing conditions related to clot formation.

Latest Patents

Park's patent, titled "Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same," highlights a groundbreaking advancement in medicine. This innovation pertains to a specific platelet aggregation inhibitor that effectively targets shear stress-induced platelet aggregation. The patent also details a pharmaceutical composition incorporating this inhibitor as an active ingredient, along with the preparation method for its synthesis.

Career Highlights

Woo Ile Park is currently employed at Shin Poong Pharmaceutical Co., Ltd., a reputable firm known for its dedication to pharmaceutical advancements. His career is marked by a commitment to innovating treatments that can significantly impact patient outcomes.

Collaborations

In his endeavors, Woo Ile Park collaborates with talented peers, including Jei Man Ryu and Dong Won Lee. Together, their collective expertise enhances the development of new therapeutic solutions in the realm of platelet aggregation and thrombotic disease prevention.

Conclusion

Woo Ile Park exemplifies the spirit of innovation in the field of pharmaceuticals. With his patent on novel compounds for inhibiting platelet aggregation and dedicated collaborations with fellow researchers, he continues to pave the way for advancements in the treatment of thrombotic diseases. His contributions are not only significant to the medical community but also offer hope for future therapeutic breakthroughs.